ANI Pharmaceuticals, Inc. (ANIP) Earnings Call Analysis

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

20/25

Growth 3 Margin 4 Expansion 5 Platform 4 Financial 4

latest quarter score

Earnings Reports

20
ANI Pharmaceuticals (ANIP) Q2 2026: Cortofan Sales Surge 43% Amid Rare Disease Expansion
August 08, 2026
20
ANI Pharmaceuticals (ANIP) Q1 2026: Cortrophin Gel Jumps 42% as Rare Disease Mix Hits 60%
May 08, 2026
16
ANI Pharmaceuticals (ANIP) Q4 2025: Rare Disease Revenue to Reach 60% of $1B+ Sales in 2026
February 27, 2026
20
ANI Pharmaceuticals (ANIP) Q3 2025: Rare Disease Revenue Surges 110%, Fueling Guidance Raise
November 07, 2025
18
ANI Pharmaceuticals (ANIP) Q2 2025: Cortrophin Gel Guidance Raised 21% as Rare Disease Momentum Accelerates
August 08, 2025
17
ANI Pharmaceuticals (ANIP) Q1 2025: Rare Disease Revenue Jumps 87% as Cortrophin Gel Expands Market Reach
July 06, 2025
ANI Pharmaceuticals (ANIP) Q4 2024: Rare Disease Revenue Doubles, Cortrophin Gel Growth Drives 45% Total Sales Increase
February 28, 2025
ANI Pharmaceuticals (ANIP) Q3 2024: Rare Disease Now 77% Growth Engine as Alimera Integration Targets $10M Synergy
November 08, 2024
ANI Pharmaceuticals (ANIP) Q2 2024: Cortrophin Gel Revenues Double, Rare Disease Now 45% of Pro Forma Sales
August 06, 2024
ANI Pharmaceuticals (ANIP) Q1 2024: Cortrophin Gel Revenue Soars 126% as Rare Disease Platform Broadens
May 10, 2024
ANI Pharmaceuticals (ANIP) Q4 2023: Cortrophin Gel Jumps 137% as Rare Disease Expansion Accelerates
February 29, 2024
22
ANI Pharmaceuticals (ANIP) Q3 2023: Rare Disease Revenue Surges 136% as Supply Chain Tailwind Moderates
November 08, 2023
ANI Pharmaceuticals (ANIP) Q2 2023: Rare Disease Revenue Surges 138%, Driving Up Full-Year Guidance
August 09, 2023
ANI Pharmaceuticals (ANIP) Q1 2023: Rare Disease Surge Lifts Guidance by $25M as Generics Outperform
May 08, 2023
ANI Pharmaceuticals (ANIP) Q4 2022: Rare Disease Revenue Set to Double, Generics Margin Expands
March 09, 2023

Browse all companies